Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.
Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle RP, Sinyavskaya L, Hlavacek P, Meche A, Ren J, Schepart A, Aydin D, Nador G, DiBonaventura MD.
Costa LJ, et al. Among authors: hlavacek p.
Future Oncol. 2024 Feb 28. doi: 10.2217/fon-2023-0995. Online ahead of print.
Future Oncol. 2024.
PMID: 38415370
Free article.